We’re experts in biometrics. We help millions of people in Africa, and other emerging markets, to identify who they are based on something unique – their own biometric data. Together with partners, we deliver large scale biometric identity programs, with particular experience in national elections and healthcare.
Our mission is to give an identity to millions of people that don’t have one. To date, we’ve helped over 110 million people across Africa to verify who they are. But, that’s just the beginning. There’s an estimated 2.4 billion people that have no legal identity – that’s no birth certificate, no ID card, no passport, nothing. Our technology and solutions, packed with over 30 granted patents, are built for the challenge.
GenKey is headquartered in the Netherlands, with offices in Africa (Ghana) and the US (Chicago). In 2011 a merger between the former GenKey and priv-ID BV, a spin-off from Philips Research, created the new GenKey.
Contact
High Tech Campus 69
5656 AG Eindhoven
the Netherlands
tel: +31 40 7513911
CoC: 17233846
Web: genkey.com
Michiel van der Veen, CEO of GenKey, a global player in biometric identity management based in Eindhoven, explains how both the healthcare industry and public health schemes could benefit from…
The first thing I’d say to innovators is to ask the patients. Patient groups are ready to support innovation, make sure we’re measuring what matters, and delivering what’s meaningful Avril…
Leadership in today’s pharmaceutical industry is no longer defined solely by the strength of a pipeline, but by the ability to anticipate change, execute consistently and adapt at scale. As…
For two decades the case for running a clinical trial in Asia was essentially arithmetic: the same study, for less money. That argument has not gone away, but it is…
Heidi Wang, recently retired CEO of OBI Pharma, transitioned from nearly three decades at Bristol-Myers Squibb (BMS) to lead the Taiwanese biotech for close to three years, aiming to advance…
Korea is a highly developed and extraordinarily fast-moving market; you simply cannot afford to lag behind Marc Franck, Managing Director of Zuellig Pharma Korea, explains why Korea has become one…
Even a truly great medicine delivers limited value if patients cannot actually benefit from it Jeong Tae Kim, General Manager of Daiichi Sankyo Korea, has spent 18 years with the…
Dr Long Jiang is the CEO of GCP ClinPlus, a Chinese CRO with operations in New Jersey. A former cardiovascular surgeon at Peking University People’s Hospital, he shifted into clinical research…
Yeul Hong Kim, R&D President of Yuhan, discusses the company’s transformation from a traditional Korean pharmaceutical business into an increasingly global innovator. He outlines Yuhan’s open innovation strategy, pipeline focus,…
Healthcare transformation across the GCC is entering a new phase, driven by major investments in precision medicine, genomics, and healthcare system modernisation, with countries such as Saudi Arabia and the…
We have the agility to move quickly, the expertise to navigate complex healthcare systems, and the commitment to bring innovative medicines to patients who are often overlooked Norgine is reshaping…
Hong Kong’s biotech capital market has completed one of the more dramatic reversals in recent years. After a brutal two-year drought in which valuations collapsed, liquidity evaporated, and companies were…
Mohamed ElShaarawy, General Manager for the United Arab Emirates at Roche Pharmaceuticals, reflects on the organisation’s role as a long-term healthcare partner aligned with the country’s ambition to build a…
As Synthon celebrates its 35th anniversary, the Dutch-headquartered complex generics specialist is entering a new phase of its evolution in the pursuit of affordable medicines worldwide. Having accelerated growth over…
Rock-bottom prices, regulatory red tape, and intense competition from Asia have made life difficult for Europe’s generics and biosimilar producers. Yet a handful of companies are not just surviving this…
Hisham Hagar is the executive country manager for Vertex Pharmaceuticals across the Gulf Cooperation Council, leading efforts to expand access to genetic therapies and strengthen healthcare partnerships in the region.…
Jurie Hwang is the Director of Public & International Affairs of KoreaBIO, the largest and most broadly constituted life sciences industry association in South Korea. With 650 member organisations spanning…
Japan is resetting itself as a clinical trial destination. Costs have halved, local data requirements are being relaxed, and the country is actively courting the global biotechs that have long…
Long regarded as a clinical trials backwater, the Middle East has experienced a tremendous surge in clinical research over the past five years. This boom is fuelled by a global…
Europe’s long-anticipated shift to a unified Health Technology Assessment framework is no longer theoretical, it is now being tested in practice. As the results from the first Joint Clinical Assessments…
Joe Yeh describes founding aetherAI to digitise pathology and embed AI into routine diagnostics, addressing inefficiency, subjectivity, and missed disease detection. He explains Taiwan’s rapid adoption, a research-driven market access…
The 2024 combination of 3P Biopharmaceuticals and Biovian gives 3PBIOVIAN greater scale and a broader technology base as Dámaso Molero Sánchez looks towards the CDMO’s next phase of growth. He…
TLC Bio’s George Yeh outlines the company’s evolution from liposomal oncology roots to advanced lipid nanoparticle platforms, including sustained-release therapies and in vivo cell therapy. He highlights a globally integrated…
For many years, the US has been considered the unequivocal champion in the global war against cancer. Not only does the country presently account for approximately 57 percent of worldwide…
Honeybear Biosciences is emerging as a pioneering force in precision oncology, leveraging its proprietary CoNectar glycan conjugation platform to advance next-generation ADCs and ARCs. Guided by a globally experienced leadership…
After six years leading the French Healthcare Alliance China, Olivier Dessajan has watched the Franco-Chinese healthcare relationship transform beyond recognition; from a one-way flow of products and partnerships into something…
A quarter-century after the Human Genome Project revolutionized biology, genomic sequencing has matured from an ambitious scientific frontier into an indispensable clinical reality. Today, molecular insights routinely guide everything from…
Hong Kong is entering a more decisive phase in its innovation journey, as Terry Wong steers HKSTP towards greater economic value and global relevance. With a stronger focus on translating…
Strong patent portfolios can create substantial commercial value for biopharma companies. As Isobel Barry, partner at life sciences-focused IP firm Carpmaels & Ransford LLP explains, opportunities to patent new small…
Harshika Sarbajna, SVP Commercial Global at Alvotech, reflects on the evolution of the US biosimilars market and the company’s strategy for scaling access across key therapeutic areas. In this interview,…
DACH should become a powerhouse for the Group Germany is emerging as a key growth and launch market for Ipsen, with the DACH region now ranking as the Group’s leading…
Biosimilars have already saved health systems billions of dollars, yet adoption still varies wildly by geography. With a wave of major biologics losing patent protection this decade, the market opportunity…
Korea’s position as a clinical trials hub did not happen overnight. The country has treated clinical development as a matter of deliberate government policy for the better part of two…
Contemporary Taiwan finds itself navigating unprecedented healthcare challenges, having transitioned into a super-aged society with unexpected speed, compounded by one of the lowest birth rates globally. In 2024, to secure…
Chinese pharmaceutical companies are increasingly seeking drug approval in the EU, US, and Australia, beyond the NMPA. Daphne Smyth of Veristat has witnessed this shift firsthand, advising sponsors on data…
Jaw-Jou Kang, Professor at NYCU, former head of Taiwan’s Food and Drug Administration and current chair of the Taiwan Society of Regulatory Affairs for Medicinal Products discusses the nation’s regulatory…
In debates over drug pricing, affordability and innovation are often framed as a zero-sum trade-off. Zeba M. Khan, Editor-in-Chief of ISPOR’s Value & Outcomes Spotlight, argues it doesn’t have to…
The goal is not only to generate scientific breakthroughs, but to ensure that these breakthroughs reach patients faster and more reliably Professor Gerd Geisslinger serves as Chair of Clinical Pharmacology…
If you concentrate on shared goals, collaboration and a unified voice follow naturally. Youngshin Lee, CEO of KRPIA, has built a career spanning more than three decades across pharmaceutical R&D,…
Europe stands at a critical moment as healthcare systems face growing pressure to accelerate patient access, adapt to more complex therapies, and remain competitive in a global innovation race increasingly…
My message is simply to continue believing in Europe Growth creates a different set of questions. Once commercial momentum is established, the challenge shifts from building a business to sustaining…
The priority should be to ensure that reimbursement systems can support sustainable healthcare budgets, timely patient access and continued pharmaceutical innovation Delivering the first approved treatment for metabolic dysfunction-associated steatohepatitis…
Kim Moran, SVP & Head of US Rare Disease at UCB, discusses how the company is building on its long-standing heritage in neurology to expand into rare and ultra-rare conditions.…
It takes a great deal to become number one in a field, but the harder challenge is staying there Joe Henein, CEO of Dubai-headquartered NewBridge Pharmaceuticals, has built one of…
Chris Posner, President of Esteve Pharmaceuticals LLC, the US affiliate of Spanish specialty player ESTEVE, speaks about the process of building its US affiliate from the ground up since joining…
Daniel Camardo is the President of Immedica Pharma US Inc. (Immedica), the US affiliate/subsidiary of Immedica Pharma AB, a Sweden-based rare disease company that entered the American market in 2024.…
Cell and gene therapies (CGTs) can now cure diseases that were untreatable a decade ago, often with a single dose. Yet most eligible patients – even those in rich countries…
Professor Do-Youn Oh discusses advances in gastrointestinal oncology, reflecting on the practice-changing TOPAZ-1 trial, Korea’s strengths in clinical research, and the importance of biomarker-driven therapies. She shares her approach to…
Andreas Schuil, Vice President & General Manager EMEA at Orchard Therapeutics, discusses the company’s gene therapy for metachromatic leukodystrophy, a devastating ultra-rare paediatric disease. He highlights challenges in access, pricing…
We have evolved well beyond the traditional CRO model Global biopharma companies are looking at Japan through a different lens, seeking partners that can navigate an increasingly complex regulatory landscape…
Successive American governments have grappled with the need to contain spiraling healthcare costs while sustaining the USA’s well-earned reputation as the number one launch market for breakthrough medical innovations. “The…
The opportunity is not simply to replicate the US model, but to understand what works in each system and build on the strengths we already have in Europe After almost…
Legend is looking at all ways to bring CAR-T to more patients, including allogeneic, autologous, and in vivo approaches Alan Bash, Interim CEO of Legend Biotech speaks about achieving the…
Our manufacturing base may be local, but the customers we serve and the products we manufacture are truly global Building on decades of microbial manufacturing expertise, Richter BioLogics is scaling…
We have set out a clear strategy, but strategy only provides direction; ultimately, trust is built through execution Europe pioneered the biosimilars industry and remains its most advanced market, yet…
Just over one year into the second Trump administration, the US healthcare and life science market is navigating a steady stream of series of unprecedented policy shifts. Long defined by…
The European Union is in the midst of the biggest shake-up of its pharmaceutical rulebook in a generation, racing to secure supply chains, speed up drug development, and keep Europe…
Across the Global South, hundreds of millions of people live without reliable access to basic healthcare. Too few doctors, too little data, and systems too fragile to scale. However, as…
The opportunity now is to ensure that the policy and access environment evolves at the same pace as the science Europe possesses one of the world’s strongest scientific ecosystems, yet…
The European Health Data Space (EHDS) is a landmark regulation designed to unify health data across the EU for both direct patient care and medical research. Writing in the April…
Whilst G7 countries have long been the traditional homes of pharmaceutical innovation, there is increased global competition, and a real risk that this longstanding leadership will be lost without concerted…
Can a medicine be considered “available” if it can’t be trusted? As Africa’s manufacturing base expands and its regulatory systems mature, that question is moving to the centre of the…
Access to capital is the difference between life and death for small biotechs and life science start-ups. But in an industry with high levels of failure and decades-long development cycles,…
A 2025 collection of perspectives from over 30 biopharmaceutical industry stakeholders finds that while patient centricity has made real progress — moving from an afterthought to an expectation in the…
Xia JIN, co-founder & CEO of Hong Kong-based immunology biotech Immuno Cure, outlines the progress of its DNA vaccine platform, highlighting strong Phase I results for an HIV therapeutic vaccine…
In recent years, Taiwan’s policymakers have been aggressively deploying a multi-layered industrial strategy – and doing so with the benefit of watching earlier regional movers stumble – in an effort…
A biochemistry PhD, Bin Li started out in Merck’s research labs before transitioning to Wall Street, where he was one of the few figures with the scientific, financial, and linguistic…
Serdar Yüksel spent two decades as a nurse before 15 years in North Rhine-Westphalia’s state parliament, and now represents the SPD on the Bundestag’s Health Committee. He discusses the jump…
Kwunho Jeong, CEO of JNPMEDI, is building an integrated clinical development platform that combines proprietary software, CRO services, and biotech investment to strengthen Asia’s drug development ecosystem. A former consultant…
Against a backdrop of rising geopolitical tension, regulatory fragmentation, and mounting pressure on Europe’s healthcare systems, Prague-headquartered Zentiva is positioning itself as a distinctly European pharmaceutical player focused on long-term…
There is a real sense of energy and ambition across the Korean biopharma industry Sungphil Kim, General Manager of Cytiva Korea, discusses his vision for strengthening Korea’s biopharma ecosystem through…
Prof. Fatma Al Jasmi, Professor of Biochemical Genetics at the UAE University’s College of Medicine & Health Science and the UAE’s first biochemical genetics consultant, has spent nearly two decades…
Petar Vazharov, CEO of Lotus Pharmaceuticals, is a medical doctor with an MBA who joined Alvogen in 2009 as one of its first international hires. After building the company’s Central…
Innovators should hold CDMOs to a high bar, and CDMOs need to step up Syed T. Husain, Chairman & CEO of Made Scientific, outlines the organization’s differentiated strategy to disrupt…
Taiwan runs one of the most cost-effective universal healthcare systems in the world, delivering near-universal coverage to 23 million people at a fraction of what comparable systems cost elsewhere. At…
Dr Abdulrazaq S. Al-Jazairi, Director of Clinical Trial Transformation at King Faisal Specialist Hospital and Research Centre, has spent more than 30 years at the institution. Trained as a cardiology…
Germany’s Medical Research Act is almost two years old. Writing in the June/July 2026 edition of DIA Global Forum, Thomas Sudhop, Claudia Riedel and Karl Broich of the Federal Institute…
What I want, more than anything, is to introduce this modality to patients as quickly and as properly as possible Jaejin Cho, CEO of CellinCells, explains how the company’s proprietary…
Yoo Jong-man, CEO of Organoid Sciences discusses the company’s pioneering work in organoid-based regenerative medicine, drug evaluation, and precision medicine. He highlights its regulatory achievements, proprietary technology platforms, global expansion,…
Brendan Shaw maps the global fallout from the Trump Administration’s Most Favoured Nation drug pricing agenda. From stalled launches to rattled health ministries, Shaw argues that MFN has thrown pharmaceutical…
Tina Graves, General Manager of GSK Taiwan, reflects on the affiliate’s strong commercial performance, the strategic shift towards specialty care and oncology, and the urgent case for repositioning adult immunisation…
Amy Adams stepped into the role of director of the National Institute of Neurological Disorders and Stroke (NINDS) at the beginning of the year after more than two decades within…
The opportunity to continue growing the organisation, while driving performance and innovation, remains a strong source of motivation Sobi’s rapid growth in Germany and across DACH-NL is opening a new…
We have set a goal that by 2027, more than 740,000 Korean patients will be benefiting from our treatments Christoph Hamann, General Manager of Merck Healthcare Korea, highlights strong momentum…
Majid Jafar, Co-Founder of the Loulou Foundation, discusses the strategic evolution of the patient research organisation that he co-founded with his wife following their daughter Alia’s diagnosis with CDKL5 Deficiency…
RNA interference (RNAi) therapeutics have the potential to redefine how certain diseases may be treated in the future, shifting the focus from managing symptoms to addressing their underlying biological cause.…
Five conferences, anxiety spreading across five continents, one unmistakable pattern: the global pharmaceutical industry is transforming at a dizzying pace. From Philadelphia to Geneva, from Istanbul to Chicago and London,…
Once regarded as a strategic afterthought by international biopharma, the Middle East has undergone a profound transformation in recent years, emerging as an early adopter of next-generation therapies for rare…
Chrys Kokino, President of Accord North America, discusses the strategic evolution of the US biosimilar market and Accord’s mission to move beyond single-asset competition toward a comprehensive treatment portfolio. Drawing…
Gilmore O’Neill, CEO of Editas Medicine, reflects on the company’s evolution from CRISPR pioneer to focused in vivo therapeutics developer. Two years into a strategic pivot, O’Neill shares the reasoning…
It is not unreasonable, at first glance, to ask why so many pharma multinationals have chosen to establish standalone affiliates in Hong Kong. After all, only 7.5 million people call…
We have spent the past decade building a strong foundation, investing in the market, expanding our capabilities, and assembling an exceptional team The US generics industry remains central to the…
Jay Iyer, CEO of the Access to Medicine Foundation, warns that rising nationalism and “onshoring” risk dismantling decades of progress in global health. As geopolitical tensions reshape how drugs are…
Mohamed Abu Shawish of Kyowa Kirin discusses how the company is reducing the time to diagnosis for rare diseases, increasing patient identification, and building local capacity across the GCC. He…
The biosimilars market is constantly evolving, so our teams need the willingness to learn, adapt, and embrace new ways of working Germany is playing an increasingly important role in Biocon’s…
A genuinely healthy lifestyle can help prevent neurodegenerative disease Charles S.Y. Yang discusses how his background in physics and quantum sensing led to the founding of MagQu, pioneering ultra-sensitive blood…
Few European pharmaceutical companies have undergone a transformation as striking as STADA’s. From its roots as a German generics business, the group has evolved into a diversified healthcare player with…
James Park discusses Lotte Biologics’ strategy to establish itself as a global CDMO through dual manufacturing hubs in the US and Korea, advanced biologics and ADC capabilities, and a strong…
Professor Stefan Vieths, president of Germany’s Paul-Ehrlich-Institut (PEI), explains how Europe’s most specialised biomedicines regulator is navigating a period of rapid transformation. Vieths traces the PEI’s 130-year evolution from a…
Mirjam Mann, Managing Director of the German Alliance for Chronic Rare Diseases (ACHSE), discusses Germany’s progress and persistent gaps in rare disease care. She highlights a challenging landscape, with fragmented…
As the world around us changes, we need to change with it Marie Antonia von Schönburg has been President and Chief Executive of the Korean-German Chamber of Commerce…
Establishing a genuine European investment promotion platform is crucial Achim Hartig, Director of Foreign Direct Investment at Germany Trade & Invest (GTAI) and Chair of the OECD Network of Investment…
Sanofi’s new CEO Belén Garijo has taken the reins of a company with healthy growth, but three recent late-stage clinical trial failures and a looming patent cliff for its biggest…
In 2024, contract manufacturers WuXi Biologics and WuXi AppTec were catapulted into global consciousness as two of five Chinese service providers deemed a US national security threat in a draft…
Sally Epstein looks at why the world’s biggest AI companies are all pivoting towards biopharmaceuticals. Epstein, an entrepreneur in residence at Cambridge Innovation Capital, argues that drug discovery – if…
As precision medicine forces biopharma to rethink how it builds, runs, and scales laboratory and manufacturing infrastructure, the industry’s next competitive advantage will be found not in discovery, but in…
Steve Kuo, Chairman of TRPMA, outlines Taiwan’s biotech strategy: strengthening clinical trial infrastructure, regulatory alignment and global partnerships. Drawing on experience across academia, government and diplomacy, he emphasises cultural change…
Sen Kuei Yeh, Chairman of Ta Fong Pharmaceutical, is the second-generation leader of one of Taiwan’s established domestic manufacturers. Joining in the 1990s, he assumed leadership in 2016 after gaining…
Excalipoint is betting that the next chapter of T-cell engagers will be written in solid tumours, where the modality is beginning to challenge the boundaries of cancer immunotherapy. Co-Founder, Chairman…
Leo Shen, General Manager of Heron Neutron, transitioned from PwC and semiconductors to healthcare, leveraging regulatory, operational, and capital-market expertise to scale boron neutron capture therapy (BNCT). Under his leadership,…
Prof Dr Markus M. Lerch, Physician-in-Chief and CEO of Munich University Hospital, oversees more than 2,000 concurrent clinical trials and a EUR 2.2 billion campus rebuild now underway in Bavaria.…
Hong Kong’s capital markets are entering a more dynamic phase, underpinned by a gradual return of international investors, a maturing innovation ecosystem, and targeted reforms aimed at improving market access…
Amgen’s trajectory in Hong Kong reflects a broader shift underway across the territory’s healthcare landscape, where data-driven care and cross-sector collaboration are converging to accelerate access to innovation. Against the…
Germany’s research-based pharmaceutical industry is approaching a defining period as mounting pressure to curb healthcare expenditure clashes with the country’s long-established ambition to remain a leading hub for innovation, scientific…
At its core, we need a reform of the welfare state. It’s indispensable, but it needs to be brought back to its core purpose: help for those who need it…
Our goal is to generate rigorous clinical data demonstrating that these therapies can deliver meaningful and lasting benefits for patients For decades, neurological diseases such as Parkinson’s disease, spinal cord…
Our mission has remained constant: to develop and provide cancer patients with precise treatment and early detection, and to improve patient outcomes Dr. Tae-You Kim, CEO and Co-Founder of IMBdx,…
The Middle East contains one of the world’s strongest concentrations of expertise in the rare blood disorder thalassaemia. The story starts with the high prevalence of this disease in the…
We need to bring together expertise in medicine, bioengineering, production technology and artificial intelligence Germany has the scientific expertise and clinical infrastructure to lead in cell and gene therapy, yet…
CAR T-cell therapies are entering a new phase of development in which the focus is increasingly shifting from scientific validation towards the practical realities of access, scalability, reimbursement, and delivery…
As global pharmaceutical companies diversify their manufacturing networks and seek trusted development partners, Taiwan’s CDMO sector is moving into sharper international focus. Drawing on decades of experience building ScinoPharm into…
America – once the undisputed global leader in medicine manufacturing – is today more reliant on pharma imports than at any time in its history. This dependence has steadily increased…
Randy Teel, President and CEO of Arvinas, outlines the company’s evolution from a Yale-founded research platform into a leader in targeted protein degradation. He explains how Arvinas is working to…
Tom Shea, Founder and CEO of Meitheal Pharmaceuticals, discusses his career across commercial and operational roles in generic injectables and the creation of Meitheal in 2017. He highlights the company’s…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Merck’s $2.13B deal with SciBrunch for KRAS G12D inhibitor SPR2015, Abogen’s $7.78B partnership with Novartis for an mRNA T-cell…
Singapore’s Health Sciences Authority has become one of the world’s most respected drug regulators, earning WHO maturity level 4 status and a seat at tables like the Access Consortium and…
David Meek, CEO of Genetix Biotherapeutics, discusses the company’s evolution from a scientific innovator into the commercial leader in curative therapy. He outlines how Genetix is scaling access to its…
Vaxcellbio aims to become a genuine game changer in the global immune cell therapy market Dr Je-Jung Lee, CEO of Vaxcellbio, discusses how his experience as a physician and immunotherapy…
Recordati Rare Diseases aims to be a trusted partner in helping patients with rare diseases reach diagnosis and appropriate care sooner Rapid access to innovation alone does not solve the…
Jungmin Rho is the Director of KOTRA – the Korea Trade-Investment Promotion Agency – and one of the organisation’s most seasoned voices on pharmaceuticals and life sciences. With more than…
Tomas Mihal, General Manager for Germany at STADA, discusses the company’s diversified three-pillar model across consumer healthcare, generics and specialty medicines, highlighting its strong German market position, agile culture and…
As China’s biotech industry races into next-generation modalities, Epigenic Therapeutics is seeking to open a new frontier by regulating gene expression without cutting DNA. In conversation with Bob Zhang, the…
Switzerland and South Korea may be separated by thousands of kilometres, but their economic relationship has never been closer. Bilateral trade reached nearly USD 8 billion in 2025, pharmaceutical flows…
Taiwan’s population of just 23 million people and contested political status should, in theory, harm its chances of becoming a globally relevant clinical trials hub. In fact, these two factors…
Collaboration across institutions is not optional – it is necessary. The pace and complexity of the challenges demand it. As CEO of TUM University Hospital Munich, Dr med Martin Siess…
The rare disease landscape is becoming increasingly sophisticated, demanding not only scientific innovation but also new approaches to access, evidence generation and patient support. Recordati Rare Diseases has built its…
What motivates me is the opportunity to improve medical practice in a meaningful way, rather than simply bringing another product to market In an industry where genuine differentiation is becoming…
Joshua Salsi, Head of North America, Biocon Biologics explains the company’s evolution into an integrated, global biosimilars company following the 2022 Viatris portfolio reacquisition. He highlights the company’s growing US…
The European Commission has set itself an ambitious target: making Europe the world’s most attractive destination for life sciences by 2030. In recent conversations with PharmaBoardroom, executives leading Europe for…
Cancer is becoming one of Europe’s defining public health and economic challenges, forcing policymakers to think far beyond treatment alone. Questions of prevention, screening, innovation, equitable access, system resilience, and…
Dr Tawfeg Ben-Omran, Division Chief of Genetic and Genomic Medicine at Sidra Medicine, discusses Qatar’s pioneering advancements in rare disease treatment. He explains how whole genome sequencing and expanded newborn…
Genmab is moving into one of the most consequential chapters in its history, as decades of antibody innovation converge with an ambition to take greater ownership of the journey from…
The global AI-in-clinical-trials market is forecast to grow at a 22.6 percent CAGR through 2030, reaching roughly USD 6.5 billion, as sponsors push CROs to demonstrate concrete efficiency gains rather…
Korea’s real strength right now is active, innovative discovery research, and that expertise, along with international networking, keeps improving Jungwon Woo, MedPacto CEO, discusses translating innovative cancer research into clinical…
Neuroscience is back. After a litany of divestments and scale backs in the 2010s, diseases of the brain are now the second-most-funded area in biotech, behind only cancer. However, this…
Ken Lee, Managing Director for Asia Pacific Clinical Business at Syneos Health, draws on a 20-year career across pharma, medicine, and CROs in Europe and Asia. He highlights Asia Pacific’s…
Germany’s future competitiveness begins with the policy decisions we make today Scientific breakthroughs alone are not enough to shape the future of healthcare. They must be matched by the right…
Mathias Hevert, third-generation leader of Hevert-Arzneimittel, has guided the family-owned company as CEO for more than 20 years. Founded in 1956, Hevert specialises in naturopathic medicines, including homoeopathic combination remedies,…
As the global clinical development landscape becomes more fragmented and competitive, biotechs increasingly need partners that can help them navigate regulatory complexity, identify the right trial locations, and generate meaningful…
The debate around Europe’s pharmaceutical future is shifting beyond innovation alone towards the broader challenge of sustaining access, strengthening resilience and creating a more competitive operating environment. Arun Narayan outlines…
Semiconductors: Silicon Powerhouse Taiwan and semiconductors – the microscopic chips inside virtually every electronic device – are inextricably linked. For a modestly sized island, Taiwan’s semiconductor dominance is extraordinary: through…
Hong Kong is repositioning itself within the global innovation landscape, moving beyond its total market-driven model to take an industry policy oriented market-driven approach. Through Office for Attracting Strategic Enterprises…
China has built one of the world’s most advanced digital health ecosystems — large, fast-moving, and integrated across hospitals, internet platforms, insurers, pharmaceutical companies, and regulators. AI is now embedded…
I believe we can position Korea as a true global leader in biohealth innovation Lee Hyung Hoon, Vice Minister at Korea’s Ministry of Health and Welfare, outlines his vision for…
Germany remains one of Europe’s most important pharmaceutical markets, combining scientific excellence, strong clinical research capabilities, and early access to innovation. Yet as breakthrough therapies become more sophisticated and global…
Europe’s place in the global biotechnology race is entering a decisive phase. Scientific excellence and industrial depth remain powerful advantages, yet intensifying competition from the United States and China is…
Patients in Japan deserve the same access to innovative treatments that patients in other markets have. Accelerating that access is what drives us Noriyuki Takai, CEO of EPS Corporation, outlines…
Boston and the Bay Area are globally renowned life science hubs, but beyond these more well-known centers of excellence lies a dense network of states and cities with enticing and…
Korea has something that very few countries can claim: high-quality healthcare data at genuine population scale JK Lee, Vice President of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA), outlines…
Our ambition is not simply to bring medicines to market, but to help improve the way dermatology patients are cared for As healthcare systems come under increasing pressure to deliver…
Germany and Europe have every reason to remain optimistic, provided we build on the strengths we already have As Europe seeks to strengthen its pharmaceutical resilience and Germany redefines its…
Drawing on a career spanning oncology drug discovery at AstraZeneca and biotech leadership as CEO of Enhanc3d Genomics, Hazel Jones is now Chief Strategy Officer at Laverock Therapeutics. We caught…
Despite its modest market size, Taiwan is proving a popular investment destination for pharma and medtech multinationals. While the island’s semiconductor industry garners more headlines and revenues, life sciences is…
Belief BioMed’s Co-Founder and CEO, Dr Jane Zheng, sets out an ambition to move gene therapy beyond scientific promise and into a scalable, globally accessible treatment model. Built on an…
Keren Haruvi, President of Sandoz North America, reflects on the company’s transformation following its spin-off from Novartis and outlines how Sandoz is positioning itself at the forefront of the evolving…
Pamela Hoffman is the president and recently appointed CEO of Padagis, a US-based generic pharmaceutical company established following the divestiture of Perrigo’s generics business. With manufacturing operations in Minnesota and…
Our objective is to navigate ongoing healthcare reforms successfully, serve as a primary growth engine for Viatris in Europe, and maximize our contribution to patient care Simon von Boeselager, Country…
Dr Gertrud Demmler of SBK, one of Germany’s largest statutory health insurance funds, describe the EUR 18 billion funding gap facing the country’s health system, what the July 2026 GKV…
Fu Feng Kuo, founder and chief executive of Jyong Biotech and its operational subsidiary Health Ever Biotech, outlines the company’s two-decade journey from botanical raw materials into a NASDAQ-listed pharmaceutical…
Europe is rewriting the rules governing medicines, innovation, and industrial competitiveness, with consequences that reach far beyond regulation alone. Pricing pressure from the United States, slower market access, rising administrative…
Stephan Pilsinger, Member of the German Bundestag (CSU) and Deputy Chair of the Health Committee, has publicly criticised the government’s savings package over cuts to organ-donation counselling — even as…
For years, Europe’s pharmaceutical sector has warned about declining competitiveness. Today, according to Nathalie Moll, Director General of EFPIA, that concern has evolved into something far more urgent. As the…
Demand for plasma-derived medicines continues to rise, bringing renewed attention to manufacturing capacity, supply resilience and the need for stronger plasma ecosystems. As Biotest enters its next phase of growth,…
As cell and gene therapies move closer to broader clinical reality, questions around manufacturing, scalability, and regulatory flexibility are becoming just as important as the science itself. Denise Gavin and…
Gerald Unden, General Manager DACH at Shionogi, believes that healthcare leadership begins with giving the patients of tomorrow a voice in the decisions made today. In this interview, he explains…
Europe accounts for a substantial share of Takeda’s business, hosts a significant slice of the company’s manufacturing footprint, and is involved in around half of its late-stage trials and priority…
Great success stories take time, great science, resilience. We built Denali with the goal of being one of those companies, not just surviving, but ultimately thriving. Ryan Watts is the…
With a career spanning senior roles at Galderma, Pierre Fabre Dermo-Cosmétique, Astellas, and Klinge Pharma, Marion Bock brings cross-channel expertise across prescription, consumer, aesthetic, and medical device categories. IBSA Germany…
The science only matters if we can bring those therapies to the people who need them As ophthalmology enters a new era shaped by aging populations, childhood myopia and medical…
Although best-known for its dermo-cosmetics, pharmaceuticals account for 50 percent of Pierre Fabre’s revenues, and the company has been engaged in cancer care for almost half a century. Now, it…
Dr David J. Rawlings is the division head of immunology at Seattle Children’s and director of the Center for Immunity and Immunotherapies at Seattle Children’s Research Institute. An immunologist and…
New legislation is putting Germany’s status as Europe’s most innovation-friendly pharma market under severe threat. Germany has long led Europe in terms of both the number of new medicines…
Seven months into the job as CEO of GSK, Luke Miels has moved faster and bigger than most expected. Having laid out an M&A strategy based around small bolt-ons at…
Lee-Cheng (LC) Liu, CEO of EirGenix, reflects on the evolution of Taiwan’s biotech sector and the company’s role within it as both a biologics CDMO and biosimilar developer. Liu discusses…
Falling prices are squeezing US generic and biosimilar manufacturers too hard, argues John Murphy III, President and CEO of the Association for Accessible Medicines (AAM). Generic prices have dropped an…
With the bioPROTAC platform, we can, in principle, degrade essentially any problematic protein Jaehyun Choi, Co-CEO of Genexine, outlines the company’s transition from its established hyFc platform towards bioPROTAC, a…
The US rare and ultra-rare disease market constitutes a cornerstone of the worldwide pharmaceutical industry, representing a full 52.3 percent of the total global market share in revenue for that…
Dr Long Sheng Fan, CEO, discusses Iridium Medical Technology’s development of a 4,000-pixel bionic retina. By leveraging Taiwan’s semiconductor expertise and AI convolution, the firm addresses retinal degeneration. Currently in…
Eight years into its shift into rare diseases, Ferrer is moving into a new phase as its pipeline matures. CEO Mario Rovirosa reflects on the setbacks and lessons shaping that…
If price is the only basis for adoption, biosimilars will not survive as a viable industry Tom Newcomer, SVP & Head of US Commercial, Samsung Bioepis, discusses the company’s evolution…
Taiwan’s investment culture remains heavily oriented toward semiconductors and electronics, and few investors are yet convinced to commit capital to biotech Dr. Lin, Founder and Chief Scientific Officer of Tripartite…
Khaled Elrefae of Recordati Rare Diseases discusses how the company is expanding its rare disease footprint across Saudi Arabia, the GCC, and the wider MENA region. He highlights the region’s…
Access works when all pieces are in place. Hearing directly from patients about what diagnosis or how a treatment impacts their lives is meaningful to everyone involved Scott Weintraub, Head…
Michala Fischer-Hansen, EVP and Head of Europe & International Markets at Lundbeck, discusses her return to pharma and Lundbeck’s focused innovator strategy, centred on neuroscience, R&D and growth through regional…
I want Wacker Biotech to be recognised for its scientific expertise, speed, collaboration, and flexibility The expectations placed on today’s CDMOs extend far beyond manufacturing capacity, demanding scientific expertise, integrated…
Novo Nordisk has rebranded as ‘Novo’ and plans to enter new therapeutic areas as part of CEO Maziar Mike Doustdar’s push to reinvigorate growth. The company has already reinvented itself…
Randy Pritchard, General Manager and Senior Vice President of Clinical Operations for North America at bioMérieux, a global leader in in vitro diagnostics, speaks about the outsized strategic weight of…
Childhood cancer survival rates in high-income countries now exceed 80 percent, but that masks a more uneven picture: paediatric drug development lags far behind adult oncology, follow-up and psychosocial care…
Building stronger bridges between Korean biotech companies and global capital will be critical to unlocking the ecosystem’s full potential Chang Woo Lee, CEO of CUROGEN, discusses translating academic science into…
Dr Jeremy Teoh of the Chinese University of Hong Kong leads a research programme spanning bladder cancer biology, surgical innovation, and translational science. From building what is believed to be…
H.E. Dr Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, sets out the emirate’s ambition to build the world’s most integrated and intelligent healthcare system.…
After years of foundational investment in genomics, population screening, and rare disease diagnostics, Gulf nations are entering a transformative era: the delivery of advanced therapeutics. The cell and gene therapy…
Kelly LoBianco, founding director of the Los Angeles County Department of Economic Opportunity, discusses how the agency is driving growth of the region’s life sciences sector. She outlines LA County’s…
Vera Zheng is Head of Greater China and Head of Asia Pacific Strategy at Parexel, one of the world’s leading clinical research organisations. With a career spanning medical marketing, brand…
Vijay Kumar is the acting director of the Office of Therapeutic Products (OTP) within the FDA’s Center for Biologics Evaluation and Research (CBER), the regulatory super office established in 2023…
When Nasha Fitter’s daughter, Amara, was diagnosed with the ultra-rare FOXG1 syndrome at just seven months old, the prognosis was stark: no speech, no independent movement, severe intellectual disability, and…
Innovation, supply security, and sustainability are intertwined challenges for healthcare systems across Europe. For CSL, these conversations are part of everyday reality, from ensuring access to plasma-derived therapies and advancing…
The future of Europe’s pharmaceutical industry will be shaped as much by manufacturing and industrial policy as by scientific innovation. Theodore Tryfon outlines how ELPEN is investing to strengthen healthcare…
We want to provide all patients – privately or publicly insured – with rapid access to innovative therapies Germany’s statutory health insurers are under growing pressure to control pharmaceutical spending…
Germany’s biotechnology sector finds itself at a critical inflection point as political ambition, scientific strength, and industrial policy begin to converge around a shared objective: positioning the country as a…
When, in his 2023 policy address, Hong Kong Chief Executive John Lee announced the territory’s intention to conduct its own primary reviews of medicines, the initial industry reaction was mixed.…
Thomas Seewoester, Vice President Site Operations and Site Head at Amgen Manufacturing Limited, LLC, has overseen Puerto Rico’s most significant manufacturing campus for three years, building on more than three…
As Europe rethinks how medicines are priced, regulated, and manufactured, the off-patent sector is moving to the centre of the policy debate. Adrian van den Hoven, Director General of Medicines…
We believe that flexibility, analytical drive, initiative, and a detailed, hands-on mindset are more important than industry experience Peter Gerckens, CEO at PharmaSGP combines a strong background in consulting, branding,…
In 2026, regulation, policy, institutions, and expertise are aligning to ensure Hong Kong can be a player in an extremely competitive Asian clinical trials landscape. From real-world data studies to…
Pamela Gavin, CEO of the National Organization for Rare Disorders, discusses NORD’s origins in the advocacy movement that led to the Orphan Drug Act and its current mission to improve…
Dr. I-Shu Lee, founder and CEO of Vitae Biomedical, began his career as a postdoctoral researcher before making the uncommon leap from academic laboratory to entrepreneurship in 2019. Built around…
Kris Hager, general manager of Bristol Myers Squibb Taiwan, discusses aligning global growth strategies with local market dynamics. With 60 years of presence in Taiwan, BMS is focused on launching…
D&D Pharmatech is emerging as one of Korea’s most closely watched clinical-stage biotechnology companies, built on more than two decades of research into GLP-1 biology and peptide engineering. With programmes…
A new generation of biotechnology companies is beginning to rethink the foundations of drug discovery. At the intersection of population genomics, biomarker-driven trials, and artificial intelligence, Halia Therapeutics is exploring…
You cannot choose between performing and transforming. The organisations that succeed can do both As AI, shifting healthcare policy, growing pressure around affordability and access, and rapidly evolving models of…
Nearly six years after becoming a standalone business, Merz Therapeutics is expanding beyond its neurotoxin heritage to build a broader specialty neurology platform across Europe and internationally. Newly appointed Region…
Scientific breakthroughs are redefining what is possible in cancer care, yet the true test lies in translating discovery into meaningful and lasting patient benefit. Michael Baumann reflects on how the…
Hideyasu Matsuda and Toru Fujieda of the Japan CRO Association argue that, thanks to an updated regulatory framework, Japan is becoming one of the most competitive and operationally attractive clinical…
What begins as frustration with the limits of academic research has developed into a story of entrepreneurship, scientific translation and sustainable biotech growth. Dr Thomas Schirrmann, Co-Founder and CEO of…
Dr Yuan-Hung Hsu, President of MegaPro Biomedical, discusses the Taiwanese company’s evolution into a late-stage nanomedicine company, with two platforms targeting precision medicine. He highlights MPB 1523, a heavy-metal-free MRI…
Dr Maisha Draves, Associate Executive Director of The Permanente Medical Group (TPMG), speaks to the group’s approach to integrating the use of biosimilars across the care network. By focusing on…
As the European Medicines Agency navigates the most significant expansion of its mandate in a generation, Executive Director Emer Cooke highlights how the regulator is further strengthening its role across…
As SyntroMed approaches its 100-year milestone, the company is entering a decisive phase of transformation, moving beyond its established OTC foundations to build a more innovation-led and internationally connected organisation.…
The US Food and Drug Administration (FDA) finds itself in the midst of unprecedented political turmoil. The Trump Administration’s Department of Government Efficiency (DOGE) removed 3,500 of the Agency’s 20,000…
Chinese biotechs are now outpacing multinationals at getting drugs into pivotal trials — but MNCs still win the race to final approval. In this piece from the September 2026 edition…
A sustainable market for generics and biosimilars is the key to lowering the cost of medicine in the US, says John Murphy III, President and CEO of the Association for…
But Korea is genuinely active, with strong resources – scientifically sound, capable, and very motivated Kyong Hwa Park, Professor of Medical Oncology at Korea University College of Medicine, reflects on…
Biosion has built a distinctive position within the new generation of Chinese biotech companies pursuing more capital-efficient, globally connected growth. Built around antibody innovation, early value creation, and selective partnering,…
We are actively evolving into a nation that discovers innovative drug candidates Korea’s clinical trial sector has spent the past two decades transforming itself from a fast follower into one…
Donghoon Lee outlines SK Biopharmaceuticals’ transformation into a global neuroscience player. He discusses the growth of its epilepsy profile, selective expansion into Parkinson’s disease and oncology, and acquisitions. Lee also…
Sidra Medicine is building a vertically integrated academic medical centre where clinical care, research, and education operate as a single system to accelerate precision medicine, particularly in rare and complex…
Susan Liao, General Manager of Everest Pharmaceutical Industrial Co., Ltd., represents the second generation of the family business founded in 1978. Trained in pharmacy with a PhD in clinical medicine,…
Growth in rare diseases is measured differently. It is not simply about launching new products, but about improving diagnosis, strengthening healthcare partnerships, and supporting patients throughout their journey. Those principles…
The biggest opportunity is to dare more, invest in promising ideas and become better at translating our excellent science into successful businesses Germany has no shortage of scientific expertise, but…
With US-China geopolitical tensions pushing multinational pharma to seek manufacturing bases outside China, does Taiwan’s CDMO sector offer a compelling alternative? Recent US policy moves could reshape the global…
Prof Dr med Hanns-Peter Knaebel has moved between the operating table, industry, and hospital leadership in his career a path that now shapes his approach to one of the more…
New Takeda CEO Julie Kim inherits a firm with flatlining growth and generic competition eating away at its lead drug’s revenues. Will three major new launches over the next year…
Our next phase of evolution is moving from pure-play generics to something more complex across branded products, biosimilars, and NCEs Punit Patel, President and CEO, of Zydus Americas, speaks about…
More than 40 years ago in 1983, the Orphan Drug Act was passed in the US to support and incentivise the development of rare disease therapies. Despite the over 6,000…
Hans Duijf, General Manager of Novo Nordisk Taiwan, has spent his entire 28-year career with the Danish pharmaceutical company, a rare tenure in today’s era of executive mobility. Duijf has…
The global contract manufacturing market is booming, but fragmented. The well-established names of the CDMO space – Lonza, Thermo Fisher, WuXi AppTec, WuXi Biologics, and Samsung Biologics – account for…
My long-term hope is that dialysis will become much less common because we are able to diagnose and treat kidney disease earlier and more effectively Prof. Dr. Jörg Latus is…
Dr Toshiaki Nagafuji leads the Innovative Drug Development Business (IDDB) at Linical after a career spanning discovery and research at Chugai and clinical development, project management, and business development at…
The EU Health Technology Assessment Regulation was implemented in January 2025 to replace 27 fragmented national evaluations with a single Joint Clinical Assessment, run in parallel with EMA review. The…
A shift is underway in how rare diseases are identified and managed across the Middle East and North Africa, as stronger diagnostic capabilities, evolving access frameworks, and growing local expertise…
Diabetes is surging in Africa. But, in a continent where healthcare systems are set up to support treatments for infectious – not non-communicable – diseases, can pharma companies step up…
Hong Kong – already Asia’s finance hub and an increasingly robust life science R&D destination – is placing huge bets on becoming the region’s prime location for developing, financing, and…
Innovation cannot stop at the laboratory door. It must extend to how therapies are developed, approved, and reimbursed Brian Campbell, Vice President and General Manager of the US for Orchard…
Multi-million dollar deals, world-first approvals, and a new willingness to be patient are transforming how Korea’s biotech sector does business. Korean biotech companies want to hold onto their molecules for…
Germany is the default first-choice European market for launching new, innovative medicines. But with the country’s pricing system under growing strain from both national and international pressures, some in the…
Transformation often reveals itself not through grand declarations, but through the decisions organisations make about where to invest, what capabilities to build, and how they choose to serve patients. At…
China has rapidly become the world’s leading country for clinical trial volume, alongside the stratospheric growth of its local biotech industry, which now accounts for almost a third of the…
Biotechnology has long been a strategic priority for Taiwan’s economic development, standing alongside ICT and semiconductors as a key pillar of growth for the island. Driven by a highly educated…
Europe’s position as a global healthcare leader is being tested by intensifying competition from both the US and China. As CSL’s Dirk Hoheisel points out, this is not because Europe…
Mohit Manrao, SVP and Head of US Oncology at AstraZeneca, leads the company’s effort to drive impact for cancer patients across the US. He elaborates on what it means to…
After a rocky couple of years, Hong Kong has defied its sceptics and definitively bounced back. As Asia’s financial capital and the bridge between mainland China and international markets, the…
Medicines regulatory agencies face enormous challenges in supporting and maintaining the safety, quality and supply of therapeutic goods in their respective countries and regions. Professor Anthony (Tony) Lawler, head of…
Dr Ali Taher, MD, PhD, FRCP, has spent more than three decades shaping the understanding and treatment of thalassemia. As Associate VP for Academic Centers at the American University of…
Leonard Paolillo, President of Merz Therapeutics North America, shares what it means to be a growing player in the specialty neurology space. Two years after the company’s acquisition of INBRIJA®…
Dr Holm Graessner has spent more than 20 years building the infrastructure that rare disease patients in Europe often lack entirely: diagnostic pathways, European reference networks, and academic drug development…
ESTEVE has successfully reshaped itself in the recent years as an integrated healthcare company with two distinct growth engines: highly specialised pharmaceuticals and a global small-molecule CDMO platform, united by…
Dr Jeongseok Lee has served as President of the Korea Biomedicine Industry Association (KoBIA) since September 2020, backed by an outstanding 35-year career in public service and longstanding leadership in…
Ajay Mahipal of India-focused healthcare impact and venture capital investment platform HealthKois argues that India’s life-sciences ecosystem is approaching an inflection point. Having built its reputation on manufacturing scale, the…
Jinhak Kim, Executive Director and President US at C&R Research, describes the company’s evolution into a global, data-driven CRO. He outlines its strategy of matching clinical trials to regions based…
Dr Lasse Lehnert, General Manager of Chugai Pharma Germany and European Director for Customer Engagement and Digital Experience, discusses the unique Roche-Chugai strategic alliance, the challenges for continued delivery of…
Thomas Madden is the CEO of Acuitas Therapeutics, the lipid nanoparticle delivery technology company whose platforms underpinned some of the most significant advances in mRNA medicine, such as the COVID-19…
Axolabs has spent more than two decades building expertise in a field that is only now beginning to reach greater clinical and commercial scale. Under CEO Susanne Leonhartsberger, the specialist…
CirCode Biomed is emerging at the forefront of a small but fast-evolving field seeking to turn circular RNA into a new class of medicines. From its roots in pioneering academic…
Translating scientific breakthroughs into products that genuinely impact patients is more challenging than it has ever been. Only ten percent of drugs that enter clinical trials ever make it all…
Money follows the science, and the science here in Bavaria is excellent Ralf Huss, Chief Executive of BioM, discusses how Bavaria has built one of Europe’s leading biotechnology ecosystems by…
Over the past three decades, Taiwan’s elderly population – defined as individuals aged 65 and older – has expanded by a staggering 152 percent. This demographic shift has introduced complex…
Seong-Wook Lee, CEO and founder of Rznomics, has spent more than two decades advancing trans-splicing ribozyme (TSR) technology as a novel RNA editing platform. After nearly 20 years in academia,…
Over three decades at Terumo, Takuya Hosogai has seen the Group evolve across businesses, markets and technologies. Now leading Terumo Europe, he discusses the region’s growing role in Pharmaceutical Solutions…
See our Cookie Privacy Policy Here
